Therapy

For active disease that fails to respond to steroids, consider infliximab ^a

Why?

• It improves symptoms and rates of remission in chronic active disease ^a
• It helps chronic abdominal or perianal fistulas heal ^a

Infliximab increases remission in chronic active disease

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
chronic active Crohn's disease a	single infusion of infliximab	placebo	remission at 12 weeks	8.0%	200% (-24% to 1100%)	6 (3 to 49)
			symptom improvement at 12 weeks	12%	240% (14% to 920%)	3 (2 to 8)
Crohn's disease with chronic abdominal or perianal fistulas a	3 infusions of infliximab	placebo	complete healing at	13%	257% (38% to 825%)	3 (2 to 6)
			50% reduction in fistulas at	26%	140% (28% to 349%)	3 (2 to 6)